In a recent study, we demonstrate that a non-anticoagulant octadecasaccharide (18-mer) can be used as a multi-target therapy in LPS and CLP sepsis murine models by modulating pro-inflammatory extracellular H3, HMGB1, and anti-inflammatory ApoA-I (Figure 3) (Liao et al., 2023). The gene discussed is HMGB1; the disease is Sepsis.